Nuformix PLC Additional New NXP002 Patent Filing (2560C)

TIDMNFX

RNS Number : 2560C

Nuformix PLC

28 September 2018

28 September 2018

Nuformix plc

("Nuformix" or the "Company")

Additional New NXP002 Patent Filing

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs is pleased to announce a new patent filing in connection with its NXP002 fibrosis programme.

Fibrotic disease is typically associated with high patient mortality, increasing prevalence and a lack of safe and effective treatments. Whilst, fibrosis treatments are in their infancy the emerging lung fibrosis market demonstrates their blockbuster potential. Markets for other fibrotic conditions are under-developed, with large and growing patient populations (e.g. the global liver disease market is predicted to reach $12.1 billion by 2022).

Using cutting-edge human tissue disease models, Nuformix has previously demonstrated the potential for NXP002 to attenuate progression in established lung and liver fibrosis. This additional patent filing provides further strength and breadth to the existing NXP002 patent portfolio to best support further development and commercialisation for its NXP002 programme.

Dr Dan Gooding, CEO, Nuformix plc, said: "NXP002 has demonstrated its broad anti-fibrotic potential with relevance to unmet needs in multiple life threatening conditions. Our additional patent filing strengthens Nuformix's ability to consider a wider range of options in the treatment of fibrosis. We hope to report shortly on the results of our extended study in idiopathic lung fibrosis using a highly innovative new human tissue model. Broadening and protecting the applications for NXP002 with this additional IP filing creates the potential to deliver wider benefit for patients whilst maximising value for investors."

www.nuformix.com

Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.

Enquiries:

 
 Nuformix plc 
  Dr Dan Gooding, Chief Executive 
  Officer                             [phone] 
 Gable Communications Ltd 
  John Bick / Justine James          [phone] 
 

About Nuformix plc www.nuformix.com

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCMMGZLZNMGRZZ

(END) Dow Jones Newswires

September 28, 2018 02:02 ET (06:02 GMT)